21633-77-2

Usage

Uses

Used in Pharmaceutical Industry:
Propionylmalonic acid diethyl ester is used as a reagent for the production of pharmaceuticals and other organic compounds. It serves as an intermediate in the synthesis of various organic compounds and is known for its potential as a building block in the development of new drugs and other chemical products.
Used in Agrochemical Industry:
Propionylmalonic acid diethyl ester is also used in the synthesis of agrochemicals, contributing to the development of new products for agricultural applications.
Safety Precautions:
It is important to handle Propionylmalonic acid diethyl ester with care, as it can be toxic if ingested or inhaled, and it may cause skin and eye irritation upon contact.

InChI:InChI=1/C10H16O5/c1-4-7(11)8(9(12)14-5-2)10(13)15-6-3/h8H,4-6H2,1-3H3

Upstream product

• 996-82-7 sodium diethylmalonate 
• 79-03-8 propionyl chloride 
• 996-82-7 sodium diethylmalonate 
• 109572-65-8 BrMgCH(CO₂Et)2 
• 105-53-3 diethyl malonate 
• 13433-00-6 diethyl aminomalonate hydrochloride 
• 137786-67-5 ethyl 3-amino-2-ethoxycarbonyl-2-butenoate 
• 570-08-1 diethyl acetylmalonate 

Downstream Products

• 101586-87-2 2,5-diethyl-3-oxo-1-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid ethyl ester 
• 99981-60-9 propionic acid-(N-ethyl-N'-phenyl-hydrazide) 
• 4949-44-4 ethyl propanoylacetate 
• 26732-70-7 1-Cyclohexyliden-hexan-4-on 
• 17094-34-7 ethyl pivaloylacetate 
• 916319-06-7 5-ethyl-2-phenyl-1,2-dihydro-pyrazol-3-one 
• 109249-29-8 1,2-dihydro-5-ethyl-1-methyl-2-phenyl-3H-pyrazol-3-one 
• 107415-39-4 1,5-diethyl-2-phenyl-1,2-dihydro-pyrazol-3-one 
• 104439-88-5 5-ethyl-2-methyl-1-phenyl-1,2-dihydro-pyrazol-3-one 
• 107417-10-7 2,5-diethyl-1-phenyl-1,2-dihydro-pyrazol-3-one 
• 100713-13-1 1,5-diethyl-4-bromo-2-phenyl-1,2-dihydro-pyrazol-3-one 
• 108953-32-8 1,5-diethyl-4-amino-2-phenyl-1,2-dihydro-pyrazol-3-one 
• 100374-11-6 1,5-diethyl-4-nitroso-2-phenyl-1,2-dihydro-pyrazol-3-one 
• 101867-69-0 1,5-diethyl-4-diethylamino-2-phenyl-1,2-dihydro-pyrazol-3-one 

Relevant academic research and scientific papers

Synthesis of β-arylacyl / β-heteroarylacyl-β-alkylidene malonates and their application in substituted pyridone synthesis

A novel approach has been developed for the synthesis of β-arylacyl/β-heteroarylacyl-β-alkylidine malonates in moderate to good yields by the reaction of Stork aryl and heteroaryl enamine with β-chloroalkylidene malonates. The reaction involves conjugate

Synthesis of novel 5-alkyl/aryl/heteroaryl substituted diethyl 3,4-dihydro-2H-pyrrole-4,4-dicarboxylates by aziridine ring expansion of 2-[(aziridin-1-yl)-1-alkyl/aryl/heteroaryl-methylene]malonic acid diethyl esters

A novel synthetic methodology has been developed for the synthesis of diethyl 5-alkyl/aryl/heteroaryl substituted 3,4-dihydro-2H-pyrrole-4,4- dicarboxylates (also called 2-substituted pyrroline-4,5-dihydro-3,3-dicarboxylic acid diethyl esters) by iodide i

PYRAZOLOOXAZOLE COMPOUND

A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism. wherein R1 and R2 are the same or different and are a hydrogen atom, a C1-6 alkyl group, a cyclic group selected from a C3-6 cycloalkyl group, a tetrahydropyranyl group, a dihydropyranyl group, a tetrahydrofuryl group, a dioxanyl group, a tetrahydrothienyl group, a dithianyl group and a hexahydrothiepinyl group, a C1-6 alkyl group substituted with a cyclic group selected from a C3-6 cycloalkyl group, a tetrahydropyranyl group, a dihydropyranyl group, a tetrahydrofuryl group, a dioxanyl group, a tetrahydrothienyl group, a dithianyl group and a hexahydrothiepinyl group, etc; R3, R4 and R5 are the same or different and are a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C1-6 alkoxy-C1-6 alkyl group, a C3-6 cycloalkoxy-C1-6 alkyl group or a halogen atom; R6 is a hydrogen atom or a C1-6 alkyl group; and R7 is a C1-6 alkyl group, a C1-6 alkoxy group or a C1-6 alkylthio group.

Organic compounds

There are described pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS

The present invention provides a compound of formula (I) or a salt thereof (in particular, a pharmaceutically acceptable salt thereof): The invention also provides the use of the compounds or salts as inhibitors of phosphodiesterase type IV (PDE4) and/or

PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS

The invention provides a compound of formula (I) or a salt thereof: wherein Ar has the sub-formula (x): and wherein: Q1 is NH or NMe, in which case Q2 is -C(O)-, -S(O)2-, -C(O)NH- or -C(O)NMe-; or Q1 is a bond o